Zenas BioPharma (ZBIO) Insider Raleigh Buys 18,500 Shares

Jason Raleigh Nunn recently purchased 18,500 shares of ZBIO on June 15, 2026. The transaction didn't specify a price or total value, but it's part of a series of insider buys on the same day, indicating a possible positive sentiment among the company's leadership.

Other Institutional Activity in ZBIO

FMR LLC increased its position in ZBIO by 1,377,745 shares, bringing its total to 9,082,000 shares worth about $177.6 million. Meanwhile, NEA Management Company, LLC also boosted its holdings by 500,000 shares, ending with 4,023,219 shares valued at approximately $78.7 million. Federated Hermes, Inc. added 411,453 shares, reaching a total of 3,127,031 shares worth $61.1 million. In contrast, SR One Capital Management, LP and Enavate Sciences GP, LLC maintained their positions without change.

Zenas BioPharma, Inc. Stock Down 41.0%

Shares of ZBIO are trading at $18.58. The stock has seen varied interest from institutional investors, as reflected in recent buying activities. The company's market dynamics and insider transactions could influence its future performance.

Insider Buying and Selling at Zenas BioPharma, Inc.

On June 15, 2026, multiple insiders, including Nunn Jason Raleigh, Boylan James, and Allen Patricia, each purchased 18,500 shares. Joseph Farmer, President and COO, acquired 175,000 shares, while Lisa Von Moltke, Head of Research and Development, bought 150,000 shares. Jennifer Fox, Chief Business Officer and CFO, purchased 125,000 shares. None of these transactions were planned trades under a Rule 10b5-1 plan.

Analysts Set New Price Targets

On May 14, 2026, Morgan Stanley maintained its hold rating on ZBIO with a $22 price target. Earlier, on March 17, Citigroup and Guggenheim reiterated their buy ratings with targets of $41 and $55, respectively. The consensus among analysts suggests a mixed outlook, with a range of price targets indicating potential volatility.

Bottom Line

The recent insider buying activity at ZBIO, including Jason Raleigh Nunn's acquisition, shows significant interest from the company's leadership. While these transactions suggest confidence, they are not definitive indicators of future stock performance. Investors often watch such insider moves closely, but it's important to remember that these are backward-looking reports and may not reflect the current situation.